Skip to main content

NextGen Discovery Series - November 16

The NextGen Precision Health Discovery Series provides learning opportunities for UM System faculty and staff across disciplines, the statewide community and our other partners to learn about the scope of precision health research and identify potential collaborative opportunities. The series consists of monthly lectures geared toward a broad multidisciplinary audience so all can participate and appreciate the spectrum of precision health efforts. 

Information about the upcoming talk, including continuing education, is available below.

For questions about this event or any others in the Discovery Series, please reach out to Mary Hindle-Christie at hindlem@health.missouri.edu

Healthy Aging, Healthy Lifestyle and Reduced Risk of Dementia

Alzheimer’s disease (AD) is a progressive mental illness, characterized by memory loss and multiple cognitive impairments with no cure. Currently, we do not have early detectable biomarkers and/or drugs that can delay progression of disease. Several years of research have revealed that physical inactivity and unhealthy diets largely involved in disease process. Dr. Reddy’s presentation covered the global impact of dementia, causal factors of disease, research developments on cellular, molecular and pathological changes in disease process. Most importantly, his presentation explained the impact of healthy aging and healthy lifestyle in delaying disease progression. Healthy aging and healthy lifestyle will help us to maintain both physical and mental health in our older age.

 

About the Speaker Reddy Headshot

Dr. Reddy is a tenured Professor and Vice Chair of Basic and Translational Research for the Department of Internal Medicine at Texas Tech University Health Sciences Center in Lubbock. Dr. Reddy is also a Professor of Neuroscience/Pharmacology, Neurology, Public Health and Speech, Language and Hearing Departments at Texas Tech. His research lab has been involved with research on healthy aging, dementia and other neurodegenerative diseases, including Huntington’s, Parkinson’s, and Multiple Sclerosis. In addition, the Reddy lab group is actively working on chronic conditions such as diabetes, obesity, cardiovascular, kidney, stroke, vascular dementia and other factors associated with dementia. Dr. Reddy is a prolific writer, author or co-author of more than 200 peer-reviewed articles/chapters/reviews, including publications in such journals as Nature Genetics, Ageing Research Reviews, Trends in Neurosciences, Trends in Molecular Medicine, Drug Discovery Today and Human Molecular Genetics. He has received research funding from the National Institutes of Health since 2002. He also serves as Chief Scientific Officer for the Lubbock-based small business company, abSynapTEX, LLC.

 

Continuing Professional Education Credit

Nurses

Up to 1.0 contact hour will be awarded to all participants who view the live sessions in their entirety and complete the evaluation form.

University of Missouri Sinclair School of Nursing is approved as a provider of nursing continuing professional development by the Midwest Multistate Division, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Midwest Multistate Division Provider Number MO1022-6

Physicians

The Office of Continuing Education, School of Medicine, University of Missouri is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The Office of Continuing Education, School of Medicine, University of Missouri designates this live educational activity for a maximum of AMA PRA Category 1 Credit(s)™.  Physicians should only claim the credit commensurate with the extent of their participation in the activity.

CONFLICT OF INTEREST: All persons with influence over the content of this program have been asked to disclose relevant financial interests in the last 12 months that might have an impact. John Spertus, MD, is a consultant for Jannsen, Bayer, Myokardia, Merck and Novartis, and receives research support from Abbott Vascular. No other speaker or planning committee member has a relevant financial interest.